< 1 min reading time
source: https://www.linkedin.com/groups/78665/78665-6174257174584320003 Marked as spam
|
Meet your next client here. Join our medical devices group community.
Private answer
Mark Proulx, CQA, cSSBB
Adrianna Davies When Johnson and Johnson comes knocking on your door wanting to purchase your company! LOL
Marked as spam
|
|
Private answer
Ken Powell
Conduct a simple economic/value in use analysis of your new product compared to existing products/techniques and quantitate its value. There are other important qualitative factors (patient safety, eliminating infection, reduced length of stay, etc.) to consider that can be quantified and put in the analysis. I have done it so many times it seems a basic and simple exercise.
Marked as spam
|
|
Private answer
Aaron Liang
Being at a medtech startup, I think the best validation is when the organization can reach its mission goals. For example, if a startup's mission is to bring innovative technology to set a new standard of care for a therapeutic intervention where there exists a gap in treatment options, then the validation of its efforts or success will be when physicians and patients adopt their technology and use it to improve patient health. Certainly the more widespread the market adoption, the stronger the validation of what they are doing and things will flow from there.
Marked as spam
|
|
Private answer
Santiago Ruiz-Valdepeñas
(...)
There are several things you can do to work on early validation: - Interview doctors, nurses , patients, etc, as soon as possible, and get them to simulate their real use of a visually realistic prototype. If you find it necessary to explain anything, that's a bad sign. - If the device is complex, launch less critical features first. Maybe in a slightly different context/aplication, maybe even outside medical. Hidden opportunities for your technology? - Ultimately, medical device development requires a higher degree of analytical, scientific work on every aspect of design, to ensure that quality goes beyond trial and error. - On the bright side, medical devices are not as subject to intangibles (taste, fashion, image) as other industries. If your device solves an important health issue and is fairly usable by health professionals and patients, the incentive to buy is much more objective, measurable and powerful than random gadgets, services or apps. Marked as spam
|
|
Private answer
Santiago Ruiz-Valdepeñas
Great topic! Starting lean and having early adopters that will accept unfinished, imperfect products gives us insight in many industries, but there is no way we can do the same with such safety critical products like medical devices, so early validation is a big challenge in our industry.
(continues) Marked as spam
|
|
Private answer
Paul Kirkby
Anything that's meets the end user needs with clinical application that suit s the costs and budget
Marked as spam
|
|
Private answer
Roman Liberson
The market evaluation, to my maind, includes: 1) number of customers/clients. It is not the same as patients, as not always the patient is a payer. I mean medical insurance programs and companies. Reimbersement clearence - codes and predicate devices may assist. 2) real price for first distributor - this it your client in the case that final customer would be supported in payment by reimbursement.
Marked as spam
|
|
Private answer
Shadow clinicians or patients using your product - make sure that it solves their problem and make sure that you fully understand what that problem is. Repeat this with different groups encompassing different skill levels and ideally in more than one country to highlight potential problems.
Marked as spam
|
|
Private answer
Prakash Pcgoliya
What about validation for components like FEP Teflon tube with R/O stripes manufactured by us ...?
Is it customer,device manufacturer ...? Marked as spam
|
|
Private answer
Marco Farina, Ph.D.
If the Value propositions are correct and the device receives the FDA/CE clearance......who will pay the device? Who is the payer? In US you have to prove to CMS that the device is more efficient of the "gold standard" otherwise no reimbursement. This means no market unless you convince private insurances to reimburse it.
Marked as spam
|
|